A practical reference on prohibited list: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-23. Anything still debated is marked as such rather than presented as settled.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Typical form of reference material |
| Solubility | Low in water; soluble in DMSO | Used to prepare stock solutions |
| Typical storage | -20 °C, desiccated, protected from light | Common laboratory practice |
| Analytical method | LC-MS/MS | Detects parent compound and metabolites |
| Common test matrix | Urine or blood | Used in anti-doping analysis |
Normally, the stereochemistry of the alkene is retained throughout the reaction, except under harsh reaction conditions. A variety of alkenes may be used, and these include both α- and β-halo-α,β unsaturated ketones, esters, and sulfoxides (which normally need a copper (I) additive to proceed), and more (see example below). Vinyl triflates are also sometimes used. Some reactions require the addition of LiCl and others are slowed down, implying that two mechanistic pathways are present.
=== Story === For the first year of development, the team focused mostly on the gameplay without narrative structure. Playtesters found the game fun but asked about what these test chambers were leading towards. This prompted the team to come up with a narrative for Portal. The team worked with Marc Laidlaw, the writer of the Valve's Half-Life series, to fit Portal into the Half-Life universe. This was done in part because of the project's limited art resources; instead of creating art assets for Portal, the team reused the Half-Life 2 assets. Laidlaw opposed the crossover, feeling it "made both universes smaller", and said later: "I just had to react as gracefully as I could to the fact that it was going there without me. It didn't make any sense except from a resource-restricted point of view." Valve hired Erik Wolpaw and Chet Faliszek to write Portal. Wolpaw felt that the constraints improved the game. The concept of a computer AI guiding the player through experimental facilities to test the portal gun was arrived at early in the writing process. They drafted early lines for a "polite" AI with humorous situations, such as requesting the player's character to "assume the party escort submission position", and found this style of approach to be well-suited to the game they wanted to create, leading to the creation of the GLaDOS character. GLaDOS was central to the plot.
== Comparison with mammalian leptin == The large differences among endothermic (warm-blooded) mammalian and ectothermic (cold-blooded) teleost leptins raised the question of whether the energy homeostatic functions of the teleost leptins are conserved. Initial phylogenetic analysis has revealed that amino acid conservation with other vertebrate Lep orthologues is low, with only 13.2% sequence identity between torafugu and human LEP. Subsequent investigations have confirmed the low amino acid identity of teleost leps compared to mammalian LEP.
Sources: en.wikipedia.org
For services to the community in Rochdale, Lancashire. Richard Douglas Williams. For services to Journalism and to the community in Cornwall. Edith Frances Williams. For services to the community in Bnslington, Bristol. John Michael Williams. For services to the community, particularly the Arts, in Buxton, Derbyshire. Lyndhurst Williams, Constable, Metropolitan Police. For services to the Police and to Industrial Relations. Richard Williams. For Political Service. Roy Williams. For Political Service. Thomas Alan Williams, Senior Scientist, Phosphates Group, Albright and Wilson Ltd. For scientific services to the Chemical Industry. Grace Ellen Wood. For services to Elderly People in Twerton, Bath. Marjorie Wood. For services to the Royal Parks of London. Margaret Jane Wooden, School Crossing Patrol, Lancashire County Council. For services to Road Safety and to the community. Alfred Thomas Woolnough, Driver, Metropolitan Police. For services to the Police. Simon William Wren, lately Higher Executive Officer, Ministry of Defence. Madge Margaret Wright. For services to Mentally Handicapped People. Fred Yallop, Emergency Engineer. For humanitarian services to the former Yugoslavia. Charles Henry Young. For services to the community in South Shields, Tyne and Wear. John Ralph Young, Technical Liaison Manager, Lever Brothers Ltd. For services to the Chemical Industry. John William Young, Brigade Treasurer, lately Chairman, England and Wales Committee, Boys' Brigade. For services to The Boys' Brigade.
David L. Eaton (born August 15, 1952) is an American toxicologist and professor Emeritus at the University of Washington (UW). His work focuses on risk assessment, gene-environment interactions, environmental carcinogenesis, and xenobiotic biotransformation. Over his career, Eaton has chaired committees for the National Academies of Sciences, Engineering, and Medicine (NASEM), held academic administration positions at the University of Washington, and presided over the Society of Toxicology (SOT).
=== Ungrouped === CTDP1 CTDSP1, CTDSP2, CTDSPL DULLARD EPM2A ILKAP MDSP PGAM5 PHLPP1, PHLPP2 PPEF1, PPEF2 PPM1A, PPM1B, PPM1D, PPM1E, PPM1F, PPM1G, PPM1H, PPM1J, PPM1K, PPM1L, PPM1M, PPM1N PPTC7 PTPMT1 SSU72 UBLCP1
Sources: en.wikipedia.org
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.
PPARδ is a nuclear receptor that regulates genes linked to fatty acid oxidation and energy metabolism. Activation can alter lipid handling and energy use in experimental models. The full range of effects in humans is still under study.
The solid compound is generally stable when kept cold, dry, and protected from light. Solutions may degrade faster, so laboratory protocols often specify fresh preparation or cold storage. Stability can depend on solvent, concentration, and container.
Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.